Acutus Medical Competitors

Cardiovascular Systems (NASDAQ:CSII) and Acutus Medical (NASDAQ:AFIB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cardiovascular Systems and Acutus Medical, as provided by MarketBeat.

Cardiovascular Systems currently has a consensus target price of $47.5714, indicating a potential upside of 31.67%. Acutus Medical has a consensus target price of $24.80, indicating a potential upside of 87.88%. Given Acutus Medical's higher possible upside, analysts clearly believe Acutus Medical is more favorable than Cardiovascular Systems.

Profitability

This table compares Cardiovascular Systems and Acutus Medical's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Cardiovascular Systems and Acutus Medical's top-line revenue, earnings per share and valuation.

Cardiovascular Systems has higher revenue and earnings than Acutus Medical.

Institutional & Insider Ownership

89.7% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 69.6% of Acutus Medical shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cardiovascular Systems beats Acutus Medical on 8 of the 11 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Acutus Medical and MiMedx Group, as reported by MarketBeat.

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. MiMedx Group has a consensus price target of $20.00, indicating a potential upside of 57.23%. Given Acutus Medical's higher possible upside, research analysts clearly believe Acutus Medical is more favorable than MiMedx Group.

Profitability

This table compares Acutus Medical and MiMedx Group's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Acutus Medical and MiMedx Group's gross revenue, earnings per share (EPS) and valuation.

MiMedx Group has higher revenue and earnings than Acutus Medical.

Insider and Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. Comparatively, 4.0% of MiMedx Group shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

MiMedx Group beats Acutus Medical on 6 of the 10 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Acutus Medical and Atrion, as reported by MarketBeat.

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. Given Acutus Medical's higher possible upside, research analysts clearly believe Acutus Medical is more favorable than Atrion.

Profitability

This table compares Acutus Medical and Atrion's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Acutus Medical and Atrion's gross revenue, earnings per share (EPS) and valuation.

Atrion has higher revenue and earnings than Acutus Medical.

Insider and Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. Comparatively, 63.2% of Atrion shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Atrion beats Acutus Medical on 6 of the 10 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Acutus Medical and SI-BONE, as reported by MarketBeat.

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. SI-BONE has a consensus price target of $32.60, indicating a potential downside of 3.44%. Given Acutus Medical's higher possible upside, research analysts clearly believe Acutus Medical is more favorable than SI-BONE.

Profitability

This table compares Acutus Medical and SI-BONE's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Acutus Medical and SI-BONE's gross revenue, earnings per share (EPS) and valuation.

SI-BONE has higher revenue and earnings than Acutus Medical.

Insider and Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. Comparatively, 65.3% of SI-BONE shares are owned by institutional investors. 15.5% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

SI-BONE beats Acutus Medical on 7 of the 11 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Insider and Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. 5.3% of Tactile Systems Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Acutus Medical and Tactile Systems Technology's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for Acutus Medical and Tactile Systems Technology, as reported by MarketBeat.

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. Tactile Systems Technology has a consensus price target of $59.00, indicating a potential upside of 9.26%. Given Acutus Medical's higher possible upside, research analysts clearly believe Acutus Medical is more favorable than Tactile Systems Technology.

Earnings and Valuation

This table compares Acutus Medical and Tactile Systems Technology's gross revenue, earnings per share (EPS) and valuation.

Tactile Systems Technology has higher revenue and earnings than Acutus Medical.

Summary

Tactile Systems Technology beats Acutus Medical on 8 of the 11 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Insider & Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are owned by institutional investors. 16.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Acutus Medical and LeMaitre Vascular's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Acutus Medical and LeMaitre Vascular, as reported by MarketBeat.

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. LeMaitre Vascular has a consensus price target of $36.60, indicating a potential downside of 28.85%. Given Acutus Medical's higher possible upside, equities analysts plainly believe Acutus Medical is more favorable than LeMaitre Vascular.

Earnings & Valuation

This table compares Acutus Medical and LeMaitre Vascular's gross revenue, earnings per share (EPS) and valuation.

LeMaitre Vascular has higher revenue and earnings than Acutus Medical.

Summary

LeMaitre Vascular beats Acutus Medical on 9 of the 11 factors compared between the two stocks.